Numerous prognostic markers have been proposed for gliomas and among these NG2/CSPG4 - a unique transmembrane chondroitin sulphate proteoglycan (CSPG) – has been suggested to be one of the foremost [11-17]. This evidence concerns the gene CSPG4 and central nervous system cancer.